Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Please provide your email address to receive an email when new articles are posted on . Despite potential side effects, bisphosphonate therapy may benefit postmenopausal women with osteoporosis by ...

Please provide your email address to receive an email when new articles are posted on . The reduced risks for osteoporotic and hip fractures with bisphosphonate therapy outweigh increased risk for ...

About a year was determined to be the minimal timing of bisphosphonate therapy for postmenopausal women with osteoporosis to reap a benefit, according to a meta-analysis. Looking at 10 randomized ...

The relative risk of an atypical femoral fracture with bisphosphonate use related to duration of therapy, with the highest risks being seen after 5 years of exposure, a nationwide study in Denmark ...

(Corrects to show Actonel is owned by Warner Chilcott, 4th paragraph) * FDA says no thigh fracture risk with bisphosphonates * Bisphosphonates such as Fosamax treat osteoporosis * FDA statement ...

hip fracture Researchers investigated whether hip fractures could be prevented with bisphosphonates in people with osteoporosis or osteopenia. A systematic review and meta-analysis found zoledronic ...

Bisphosphonates have been shown to reduce the risk of osteoporotic fractures. To avoid possible side effects of long-term therapy, many patients take a drug holiday after several years of ...

In a national study of older Danes who had previously had a fracture and were taking bisphosphonates, the risk of having a serious though rare atypical femoral fracture (AFF) was greater after 3 to 5 ...

Bisphosphonates are effective in reducing hip and osteoporotic fractures. However, concerns about atypical femur fractures have contributed to substantially decreased bisphosphonate use, and the ...

In patients with asthma, exposure to bisphosphonate was associated with an increased risk of atypical subtrochanteric (ST)/femoral shaft (FS) fractures. A higher cumulative dose and longer duration of ...